Q Therapeutics

Executive Summary

Q Therapeutics is a private biotechnology company developing innovative human cell-based therapies for debilitating and incurable central nervous system (CNS) diseases. Founded in 2002 and headquartered in Salt Lake City, Utah, the company employs a unique approach focused on glial cells—non-neuronal cells that support, repair, and maintain neuronal function and health. By targeting glial dysfunction, Q Therapeutics aims to address a wide range of CNS disorders, including neurodegenerative diseases and spinal cord injuries. The company's lead program is believed to be in Phase 1/2 clinical development, leveraging its proprietary cell therapy platform to restore glial cell function. Despite limited public information, Q Therapeutics has garnered interest due to its differentiated strategy in the CNS space, which has historically seen high unmet medical need and few successful therapies. The company's long operating history suggests resilience and deep expertise in cell therapy manufacturing and regulatory pathways. Given the early clinical stage and lack of recent funding or valuation data, the company remains a high-risk, high-reward opportunity with significant potential upside if its platform demonstrates safety and efficacy in ongoing trials.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 Clinical Data Readout30% success
• Q2 2026Regulatory Milestone (FDA Meeting or IND Update)40% success
• H2 2026Strategic Partnership or Licensing Deal25% success